Timothy Anthony Yap, M.D., et. al. Association of a Predictive RNA Signature (RS) With Emergence of ICOS hi CD4 T Cells and Efficacy Outcomes for the ICOS Agonist Vopratelimab (vopra) and Nivolumab (nivo) in Patients (pts) on the ICONIC Trial. Presented at ASCO-SITC Clinical Immuno-Oncology Symposium, February 6, 2020.